BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology

BACE1 is the rate-limiting protease in the production of synaptotoxic β-amyloid (Aβ) species and hence one of the prime drug targets for potential therapy of Alzheimer’s disease (AD). However, so far pharmacological BACE1 inhibition failed to rescue the cognitive decline in mild-to-moderate AD patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Peters, Finn, Salihoglu, Hazal, Rodrigues, Eva, Herzog, Etienne, Blume, Tanja, Filser, Severin, Dorostkar, Mario, Shimshek, Derya R., Brose, Nils, Neumann, Ulf, Herms, Jochen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5904228/
https://www.ncbi.nlm.nih.gov/pubmed/29327084
http://dx.doi.org/10.1007/s00401-017-1804-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5904228/
https://www.ncbi.nlm.nih.gov/pubmed/29327084
http://dx.doi.org/10.1007/s00401-017-1804-9

Ejemplares similares